TITLE

Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia

AUTHOR(S)
Bozkurt, Sureyya; Uz, Burak; Buyukasik, Yahya; Bektas, Ozlen; Inanc, Ayten; Goker, Hakan; Kansu, Emin
PUB. DATE
March 2013
SOURCE
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Additional chromosomal abnormalities (ACAs) in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) are strongly associated with disease progression, but their prognostic impact and effect on treatment response are not clear. While the onset of ACAs in Ph-negative cells during treatment has been described, their origin and clinical significance remain to be clarified. Between January 2008 and January 2011, 105 patients with Ph-positive CML were analyzed. With a median follow-up of 25.5 months, 18 CML patients (17 %) with ACAs in either CP ( n = 12) or advanced phases ( n = 6) were identified. The median age of the patients was 53.5 years at diagnosis. ACAs were determined in Ph-positive metaphases of 12 patients and in Ph-negative metaphases of 5 patients. One patient showed trisomy 8 both in Ph-positive and in Ph-negative metaphases. The median follow-up after the detection of ACAs was 11.9 months. None of the patients carrying ACAs in their Ph-negative metaphases developed AP or BP; however, 7 out of 12 patients (58 %) having ACAs in their Ph-positive metaphases developed AP/BC at diagnosis or follow-up ( p = 0.03). All the patients carrying ACAs in only Ph-negative metaphases achieved optimal response under tyrosine kinase inhibitor (TKI) therapy, whereas only 4 out of 12 patients (25 %) had optimal TKI response in patients with ACAs in Ph-positive metaphases ( p = 0.009). The presence of ACAs in Ph-positive cells during TKI therapy may reflect genetic instability and therefore negatively affect OS. Conventional cytogenic analyses remain mandatory during follow-up of patients with CML under TKI therapy.
ACCESSION #
85859848

 

Related Articles

  • LMC en 2012. Schneider, Maurice // Oncologie;Oct2012, Vol. 14 Issue 10/11, p623 

    No abstract available.

  • Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase. Hao Jiang; Shan-Shan Chen; Bin Jiang; Qian Jiang; Ya-Zhen Qin; Yue-Yun Lai; Xiao-Jun Huang // Annals of Hematology;Jan2011, Vol. 90 Issue 1, p41 

    The purpose of our study is to compare the 7-year response to imatinib monotherapy as an initial treatment and re-treatment in Chinese patients with chronic myelogenous leukemia-chronic phase (CML-CP) patients in a single center in Beijing. A retrospective study of 171 CML-CP patients receiving...

  • Imatinib.  // Reactions Weekly;11/15/2008, Issue 1228, p23 

    The article describes the case of a 70-year-old man who developed chromosomal abnormalities. The patient acquired the said condition while undergoing treatment with imatinib for chronic myeloid leukaemia. After 4 months of taking the drug, the patient developed progressive pancytopenia. The...

  • Recurrent Monosomies Confirmed by Interphase FISH in Three Chronic Myeloid Leukemia Cases. Argüden, Yelda Tarkan; Kuru, Dilhan; Çırakoğlu, Ayşe; Yılmaz, Şükriye; Aydın, Şeniz Öngören; Ar, Cem Muhlis; Deviren, Ayhan; Soysal, Teoman; Hacıhanefioğlu, Seniha // Turkish Journal of Hematology;2015, Vol. 32 Issue 1, p82 

    The article presents a case study of three patients with chronic myeloid leukemia who underwent fluorescence in situ hybridization (FISH) to evaluate significance of these recurrent monosomies. It mentions that patients were treated with imatinib. The study highlights the effectiveness of FISH...

  • Successful pregnancy and delivery in a patient with chronic myeloid leukemia: a case report and review of the literature. Sheng, Weiwei; Sun, Naitong // SpringerPlus;11/30/2016, Vol. 5 Issue 1, p1 

    Introduction: Complications associated with chronic myeloid leukemia (CML) during pregnancy are rare, and management is challenging because very limited data are available on this patient group. Case description: We herein report a successful pregnancy and delivery in a patient diagnosed with...

  • CML Treatment in the Elderly: Imatinib Levels the Playing Field. Artz, Andrew S. // Clinical Oncology Alert;Jul2011, Vol. 27 Issue 7, p52 

    In this article the author discusses a study by G. Gugliotta and colleagues on the benefits of imatinib for reducing the negative prognostic impact of age on disease response for chronic myeloid leukemia (CML) chronic phase. He comments that the study considered imatinib therapy could result in...

  • Standardized definitions of molecular response in chronic myeloid leukemia. Cross, N C P; White, H E; Müller, M C; Saglio, G; Hochhaus, A // Leukemia (08876924);Oct2012, Vol. 26 Issue 10, p2172 

    The International Randomized Study of Interferon and STI571 (IRIS) demonstrated long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with the tyrosine kinase inhibitor (TKI) imatinib. However, deep molecular responses (MRs), as measured by...

  • Philadelphia Chromosome-Positive Acute Myeloid Leukemia: A Rare Aggressive Leukemia With Clinicopathologic Features Distinct From Chronic Myeloid Leukemia in Myeloid Blast Crisis. Chad Soupir; Jo-Anne Vergilio; Paola Cin; Alona Muzikansky; Hagop Kantarjian; Dan Jones; Robert Hasserjian // American Journal of Clinical Pathology;Apr2007, Vol. 127 Issue 4, p642 

    We performed a multi-institutional retrospective analysis of the morphologic features, immunophenotype, cytogenetics, and BCR-ABL transcript characterization of cases of Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML). We compared these cases with cases of documented chronic...

  • CHRONIC MYELOID LEUKEMIA WITH HYPERDIPLOIDY: A CASE REPORT WITH REVIEW OF LITERATURE. BELURKAR, SUSHMA; MANOHAR, CHETHAN; KURIEN, ANNAMMA // Indian Journal of Medical Sciences;Jul/Aug2013, Vol. 67 Issue 7/8, p188 

    Chronic myeloid leukemia (CML) is a common marrow stem cell neoplasm characterized by the presence of the Philadelphia (Ph) chromosome in more than 90% of patients. Studies have shown that CML can be associated with various other cytogenetic abnormalities. 5-10% of these cases can show complex...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics